Shingrix under renewed scrutiny as researchers flag potential cardiovascular benefits, alongside a broader vaccine-safety review led by Kennedy administration health efforts.
A Nature Medicine study using US health records finds that older adults vaccinated with Shingrix show a reduced risk of cardiovascular disease over seven years. Experts say the vaccine could lower deaths if UK uptake rises, with ongoing trials exploring broader heart-brain protection.